TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection as documented by screening plasma HIV-1 RNA \>1000 c/mL~* ART-naïve (short-term antiretroviral use for prevention of mother-to-child transmission will be allowed) or~* ART treatment interrupters on ART \<6 months prior to interruption or virologically suppressed (\<50 copies/mL or LDL) \<6 months prior to interruption~* On rifampicin-based therapy for tuberculosis for \<3 months~* CD4 counts \>100 cells/µL~* Women of child-bearing potential willing to use adequate contraception (defined as either an intrauterine contraceptive device or hormonal contraception as per national guidelines)~Exclusion Criteria:~* Pregnant/breastfeeding~* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 (calculated by the Modification of Diet in Renal Disease (MDRD) study)~* Alanine aminotransferase \>3 times upper limit of normal (ULN)~* Allergy or intolerance to one of the drugs in regimen~* Concomitant medication known to significantly reduce or increase dolutegravir exposure (except rifampicin)~* Active psychiatric disease or substance abuse~* On treatment for active AIDS-defining condition other than tuberculosis (participants on maintenance therapy may be enrolled)~* Malignancy~* Any other clinical condition that in the opinion of an investigator puts the patient at increased risk of participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Supplementary dose (Type: ACTIVE_COMPARATOR): Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
- Placebo dose (Type: PLACEBO_COMPARATOR): Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently participating in Study MLN-MD-06~* Receiving a stable dosage of milnacipran (50-200 mg/d) at Screening/Enrollment (Visit 1)~Exclusion Criteria:~* Significant risk of suicide~* History of mania, bipolar disorder, psychotic disorder, schizophrenia, or a current episode of major depressive disorder~* Myocardial infarction and/or stroke within the prior 12 months~* Mean systolic blood pressure \> 180 mm Hg or mean diastolic blood pressure \> 110 mm Hg at Screening (Visit 1)~* Active liver disease~* Severe renal impairment~* Platelet and bleeding disorders~* Female patients who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo tablets administered orally twice daily
- 2 (Type: EXPERIMENTAL): Milnacipran tablets administered orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective~* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2~* Life expectancy greater than 3 months~* Adequate organ and marrow function~* Written informed consent~* Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study~* In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST~Exclusion Criteria:~* Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184~* Administration of an investigational drug within 30 days of the first dose of XL184~* Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment~* Known brain metastases~* Uncontrolled intercurrent illness~* Pregnancy or breastfeeding~* Known HIV positive~* Known allergy or hypersensitivity to any of the components of the XL184 formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nephropathy In Type 2 Diabetes and Cardio-renal Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetic patients~* albumin extraction rate (AER= \>30 mg/die (micro- or macro-albuminuric ranges) in at least two determinations in the last six months~* diabetic retinopathy~* patients followed in the outpatients clinic for at least 12 months~Exclusion Criteria:~* type 1 diabetic patients~* \<40 years old

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SoC) therapy (Type: ACTIVE_COMPARATOR): Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
- Multifactorial Intensified therapy (Type: EXPERIMENTAL): An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (\<130/80 mmHg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age between 37 and 42 weeks~* singleton pregnancy~* live fetus~* cephalic presentation~* neonatal birth weight of 2500-4500 g~* parity between one and five~* maternal age \< 35 years~* vaginal birth~Exclusion Criteria:~* blood pressure ≥ 140/90mmHg~* placenta previa~* placental abruption~* a history of any bleeding during pregnancy~* a history of curettage~* cesarean section or any uterine scar~* a history of postpartum hemorrhage~* polyhydramnios~* signs or symptoms of maternal infection~* known uterine anomalies~* history of any drug use during labor~* abnormal placentation)~* coagulation defects~* instrumental deliveries~* hemoglobin concentration \< 8 g/dL~* history of anticoagulant drugs~* beta-mimetic medications during pregnancy~* prolongation of the first stage of labor \> 15 hours.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Saline group (Type: EXPERIMENTAL): Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must receive once daily oral methadone maintenance therapy at a stable individualized dose of 30 to 130 mg for at least 2 weeks prior to screening, formulated as commercially available tablets or solution~* Must agree not to change the current methadone dose from screening until Day 7 included to have a daily observed and documented methadone intake from Day -14 until Day 8 and a daily observed and documented telaprevir intake from Day 1 until Day 7~* Participants have to obtain approval for participation from his/her addiction physician, and the addiction physician has to agree to provide medical care for the participant after discharge from study center~* General medical condition must not interfere with the assessments and the completion of the study~* Health assessments will be done on the basis of physical examination, medical history, electrocardiogram, vital signs and the results of blood biochemistry, blood coagulation and hematology tests and a urinalysis carried out at screening~Exclusion Criteria:~* History of any illness that could confound the results of the study or pose an additional risk in administering study medication to the participant, for eg, history of relevant medication or food allergies, history of cardiovascular or central nervous system disease, history or presence of clinically significant pathology or history of mental disease~* Consumption of herbal medications or dietary supplements, vitamins, and grapefruit or grapefruit juice, apple juice or orange juice within 14 days before Day -1~* Current alcohol use, which, in the assessment of the investigator, could compromise participant's safety or compliance with the study protocol procedures~* Test positive for drugs of abuse such as cocaine, amphetamines, barbiturates, benzodiazepines, or opiates on Day -2 unless explained by allowed concomitant medications~* Participation in a clinical study involving administration of an investigational medication within 60 days or 5 half-lives (whichever was longer) prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Telaprevir + Methadone (Type: EXPERIMENTAL): Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 5 years of age.~* Documented clinical diagnosis of MPS IVA based on clinical signs and symptoms of MPS IVA and documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic testing confirming diagnosis of MPS IVA.~* Willing and able to provide written, signed informed consent, or in the case of patients under the age of 18 (or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.~* Must meet the study entrance requirements for the 6-minute walk test.~* Sexually active patients must be willing to use an acceptable method of contraception while participating in the study.~* Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study.~Exclusion Criteria:~* Previous hematopoietic stem cell transplant (HSCT).~* Previous treatment with BMN 110.~* Has known hypersensitivity to any of the components of BMN 110.~* Major surgery within 3 months prior to study entry or planned major surgery during the 24-week treatment period.~* Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.~* Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.~* Concurrent disease or condition, including but not limited to symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation or safety as determined by the Investigator.~* Any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- BMN 110 Weekly (Type: EXPERIMENTAL): None
- BMN 110 Every Other Week (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misopristol Versus Pitocin for Second Trimester Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* midtrimester late abortion~* midtrimester induced abortion~Exclusion Criteria:~* placenta previa~* infected abortion~* rupture of membranes~* s/p cesarean section \*2 or more

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- pitocin (Type: ACTIVE_COMPARATOR): high dose pitocin drip 48 hours after mifepristone preparation.
- misopristol (Type: ACTIVE_COMPARATOR): vaginal and oral misopristol 48 hours after mifepristone preparation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects with good general health as judged by the Investigator~* Body weight of 65.0-95.0 kg (both inclusive)~* Body Mass Index (BMI) of 18.5-27.5 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Known or suspected allergy to trial product or related products~* Acute infection or inflammation or other illness that may confound the results of the trial or pose a risk to the subject by administering the trial product, as judged by the Investigator~* Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) or malabsorptive states (celiac disease, lactose intolerance or chronic pancreatitits), as judged by the Investigator

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Trial part 1 (Type: EXPERIMENTAL): None
- Trial part 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease~* History of at least one unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Diabetes mellitus~* Change in body weight greater than 5 kg within 3 months prior to starting study~* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity~* History of pancreatitis~* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Any lifetime history of a suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tirzepatide (lead-in) (Type: EXPERIMENTAL): Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
- Tirzepatide MTD (Type: EXPERIMENTAL): Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received weekly doses of placebo SC for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Inflammatory Effects of Pioglitazone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between the ages of 35 and 85 years~* Subjects with impaired glucose tolerance and type 2 diabetes, who had atherosclerosis detected by carotid ultrasound and/or CT~* Subjects who had vascular FDG uptake by FDG-PET~Exclusion Criteria:~* Subjects with insulin treatment~* Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease~* Subjects taking more than three antidiabetic medications~* Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones (TZDs) within 8 weeks prior to randomization~* Subjects with cardiac failure (New York Heart Association Class \> III) or left ventricular dysfunction (LVEF \< 40%)~* Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): up to 30 mg pioglitazone, tablet, orally, once daily
- 2 (Type: ACTIVE_COMPARATOR): up to 4 mg/day glimepiride, tablet, orally, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria At Screening:~* Male or female asthmatics, any racial group. Females of childbearing potential must practise two forms of contraception~* Non smokers~* Mild to moderate asthmatics according to GINA guidelines for at least 12 months.~* History of asthma symptoms increasing in response to external allergens.~* Testing positive on skin prick test to an allergen associated with the subject's asthma~Exclusion Criteria:~* Use of inhaled or local corticosteroids in the period from 28 days prior to screening.~* Receipt of prescribed or over the counter medication within 14 days of the first study day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- OC000459 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete